Fetal derived stem cells for Parkinson’s disease

Undifferentiated human fetal brain-derived stem cells grafted into putamina of parkinsonian patients is safe and moderately effective: a phase I clinical trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN39104513

Enrollment

Registered

2016-05-04

Start date

2011-06-01

Completion date

Unknown

Last updated

2019-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease Nervous System Diseases

Interventions

Stereotactical transplant of stem cells into both putamina. One million million stem cells were deposited in two areas (anterior and posterior) of both putamina. All of this is by one trephine in the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy patient with Parkinson's Disease

Exclusion criteria

Exclusion criteria: 1. Pregnancy 2. Secondary pathology

Design outcomes

Primary

Measure	Time frame
1. Safety of transplantation of cells, measured by recording side effects or complications arising after surgery. 2. Degree of motor improvement, measured using the unified Parkinson's disease rating scale (UPDRS) score	—

Secondary

Measure	Time frame
1. Cognitive performance, measured using the mini–mental state examination (MMSE) score at baseline and at 1 year follow-up 2. Uptake patterns of DTBZ, FDOPA and RAC	—

Countries

Mexico

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 22, 2026